Valuation: Evotec SE

Market Cap 888M 1.01B 818M 762M 1.44B 96.2B 1.47B 9.84B 3.81B 47.22B 3.8B 3.72B 164B P/E 2026 *
-7.03x
P/E 2027 * -25.6x
Enterprise Value 903M 1.03B 831M 774M 1.46B 97.75B 1.49B 9.99B 3.87B 47.98B 3.86B 3.78B 167B EV / Sales 2026 *
1.22x
EV / Sales 2027 * 1.17x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 day+2.14%
1 week+5.93%
Current month+1.94%
1 month-3.96%
3 months+14.31%
6 months-7.73%
Current year-6.51%
1 week 4.7
Extreme 4.698
5.23
1 month 4.52
Extreme 4.516
5.33
Current year 4
Extreme 3.995
6.73
1 year 4
Extreme 3.995
7.84
3 years 4
Extreme 3.995
24.44
5 years 4
Extreme 3.995
45.83
10 years 3.64
Extreme 3.641
45.83
Manager TitleAgeSince
Chief Executive Officer 55 30/06/2024
Director of Finance/CFO - 30/04/2026
Chief Operating Officer - 30/04/2026
Director TitleAgeSince
Director/Board Member 58 18/06/2019
Director/Board Member 64 31/05/2021
Director/Board Member 43 21/06/2022
Date Insider Type Main position Quantity % Market Cap.
06-14Sell

Chief Technology Officer

-119,900 0.0674%
05-19Fiscal year

Chief Technology Officer

12,462 0.0070%
05-03Buy 15,510 0.0087%
Change 5-day change 1-year change 3-year change Capi.($)
+1.94%+5.93%-29.72%-74.58% 1.01B
+3.08%+6.47%-0.25%+6.27% 47.18B
-0.88%+9.45%+403.69%+592.55% 39.82B
+5.63%+10.24%+25.84%-7.44% 32.25B
+2.49%+5.03%+18.72%+60.94% 31.68B
+0.69%+8.72%+14.80%+30.86% 24.59B
-0.23%+12.06% - - 16.57B
+3.59%+6.94%+70.80%+129.40% 15.12B
-0.15%+2.15%+12.64%+17.55% 13.69B
-0.98%+2.27%+95.94%+90.51% 13.1B
Average +1.54%+7.26%+68.05%+94.01% 23.5B
Weighted average by Cap. +1.79%+7.40%+93.03%+135.71%

Financials

2026 *2027 *
Net sales 738M 840M 679M 633M 1.19B 79.87B 1.22B 8.17B 3.16B 39.2B 3.15B 3.09B 136B 818M 931M 753M 701M 1.32B 88.56B 1.35B 9.05B 3.51B 43.47B 3.5B 3.42B 151B
Net income -113M -129M -104M -97.12M -183M -12.26B -187M -1.25B -486M -6.02B -484M -474M -20.95B -30.42M -34.65M -28M -26.09M -49.21M -3.29B -50.21M -337M -130M -1.62B -130M -127M -5.63B
Net Debt 14.3M 16.29M 13.16M 12.27M 23.13M 1.55B 23.6M 158M 61.34M 760M 61.15M 59.83M 2.65B 69.32M 78.96M 63.81M 59.46M 112M 7.51B 114M 767M 297M 3.68B 296M 290M 12.82B
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,526
Date Price Change Volume
01/07/26 5.095 +1.94% 716,379
30/06/26 €4.998 +0.60% 670,836
29/06/26 €4.968 +1.26% 454,845
26/06/26 €4.906 +1.41% 459,786
25/06/26 €4.838 +0.58% 705,454
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
4.998EUR
Average target price
6.871EUR
Spread / Average Target
+37.48%

Quarterly revenue - Rate of surprise